PAH in 2019 & beyond: Sharing experiences & real-world data
The faculty will explore real-world data on targeting the prostacyclin pathway in clinical practice, and highlight key features of ongoing studies. Personal experience with the use of selexipag in the management of PAH patients will be shared.
- To discuss and explain the new data on the use of therapies targeting the prostacyclin pathway in the real world, including personal clinical experience with selexipag
- Professor Nick Kim
- Professor Vallerie McLaughlin